Tandem Diabetes Care shares are trading lower after the company reported mixed Q2 financial results. Following earnings, Citigroup downgraded the stock from Buy to Neutral and lowered its price target from $45 to $33.
Portfolio Pulse from Benzinga Newsdesk
Tandem Diabetes Care reported mixed Q2 financial results, leading to a drop in its share price. Citigroup downgraded the stock from Buy to Neutral and lowered its price target from $45 to $33.
August 04, 2023 | 3:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tandem Diabetes Care's mixed Q2 results and Citigroup's downgrade from Buy to Neutral, along with a lowered price target, may negatively impact the stock's short-term performance.
Tandem Diabetes Care's mixed Q2 results indicate potential financial instability, which is further compounded by Citigroup's downgrade and lowered price target. This combination of factors is likely to negatively impact investor sentiment and the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100